Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing